Source: Targeted Oncology, May 2025
Melanoma remains a formidable challenge in oncology, particularly in its advanced stages. Over the past decade, however, the treatment landscape has transformed with immune checkpoint inhibitors (ICIs) and targeted therapies. The emergence of CTLA-4, PD-1, and PD-L1 inhibitors, along with BRAF and MEK inhibitors, has significantly improved outcomes.1
“The key question in melanoma today is how to extend these therapies to maximize their benefit,” James W. Smithy, MD, MHS, a melanoma medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, New York, New York, told Targeted Therapies in Oncology in an interview.